Standard BioTools Inc.
LAB
$0.90
-$0.06-6.34%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 19.61% | -62.61% | -65.23% | 3.25% | -24.80% |
| Total Depreciation and Amortization | -12.71% | 157.22% | 8.16% | -16.89% | 13.56% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,022.61% | 1,484.74% | 753.37% | 1,976.88% | -118.19% |
| Change in Net Operating Assets | -78.68% | 83.13% | 29.36% | 26.43% | -1,176.47% |
| Cash from Operations | 48.18% | 39.21% | 26.87% | -14.37% | -231.40% |
| Capital Expenditure | -29.37% | -259.96% | -613.04% | -310.88% | -126.70% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -100.49% | -100.49% | -100.49% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -12.23% | 2,693.85% | 319.20% | 21.53% | 76.38% |
| Cash from Investing | -92.45% | -81.14% | -87.89% | -79.77% | 1,694.60% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -482.50% | -435.28% | -435.28% | -2,933.70% |
| Issuance of Common Stock | 58.50% | 48.48% | 57.24% | -34.04% | -19.59% |
| Repurchase of Common Stock | 95.67% | 96.44% | 96.90% | 98.86% | -101.39% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | 100.00% | 100.00% | -- |
| Cash from Financing | 100.56% | -11.14% | -8.35% | -245.77% | -1,407.06% |
| Foreign Exchange rate Adjustments | 220.98% | 439.20% | 658.06% | -3,080.00% | -2,147.06% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -139.14% | -160.79% | -185.86% | -177.56% | 490.01% |